Journey Medical (DERM) Q4 2025: MROSI Scripts Annualize at 126,000, Driving Margin Expansion and Brand Penetration
Journey Medical’s launch of MROSI, its internally developed oral rosacea therapy, redefined the company’s growth trajectory in 2025 as prescription volumes rapidly scaled and gross margins improved despite legacy product headwinds. The company’s focus on payer access, prescriber expansion, and margin leverage positions it for continued profitability and commercial inflection in 2026. Investors should track the interplay between prescription demand, reimbursement progress, and new product launches as the company pivots toward a branded dermatology portfolio.
Summary
- MROSI Brand Penetration Accelerates: Rapid prescriber adoption and refill rates signal durable market entry.
- Margin Expansion Outpaces Legacy Drag: Improved product mix and disciplined cost control offset generic competition.
- 2026 Leverage Hinges on Payer Access: Commercial coverage, gross-to-net improvement, and new launches will drive next-stage growth.
Performance Analysis
Journey Medical’s 2025 results highlight a decisive shift toward branded dermatology, anchored by the launch of MROSI, its oral rosacea therapy. MROSI generated $14.7 million in net sales in its first three quarters, with prescription volume reaching 53,000 scripts for the year. The Q4 run-rate annualizes at over 126,000 scripts, reflecting strong sequential acceleration and early brand stickiness, as evidenced by a refill-to-new script ratio rising from 1.0 in Q3 to 1.4 by year-end.
Gross margin expanded to 66.2%, up nearly 3.5 percentage points year-over-year, driven by a favorable shift toward higher-margin products like MROSI and QBREXA, and lower inventory-related costs. Operating leverage was achieved despite a 10% increase in SG&A, tied directly to commercial investments for the MROSI launch. Legacy products, including Accutane, faced ongoing generic pressure, but the base business stabilized in late 2025, providing a more predictable foundation for incremental product launches in 2026.
- Brand Uptake Surpasses Early Targets: Over 3,500 unique dermatology prescribers have written at least one MROSI script, exceeding initial goals and signaling broadening market reach.
- Prescription-Revenue Disconnect Remains: Prescription demand outpaces reported revenue as payer coverage and formulary access lag, but management expects this gap to close as contracts mature in 2026.
- Profitability Milestone Achieved: Positive adjusted EBITDA and positive EBITDA in Q4 mark a critical inflection, supporting Journey’s claim of sustainable profitability going forward.
Cash and working capital positions are robust, with $24.1 million in cash and a $29.4 million working capital balance at year-end, giving Journey the resources to fund commercial expansion and new launches without immediate capital needs.
Executive Commentary
"2025 was a milestone year for Journey Medical, as we successfully launched MROSI, our internally developed, best-in-class oral treatment for the inflammatory lesions of rosacea... Our business was able to make solid financial progress despite pressure on our Accutane franchise and other legacy products due to generic competition."
Claude Morali, Co-Founder, President & Chief Executive Officer
"We delivered a year of strong execution... improved gross margins versus the prior year, reflecting a more favorable product mix and operating leverage, resulting in narrow net losses and positive adjusted EBITDA. Importantly, we closed 2025 with a healthy cash position that we believe supports our ongoing operations and commercial growth into the foreseeable future."
Joseph Binesh, Chief Financial Officer
Strategic Positioning
1. MROSI Launch as Flagship Growth Engine
MROSI, internally developed oral rosacea therapy, has rapidly become Journey’s core value driver. The brand’s superior efficacy versus Oracea, rapid onset, and favorable safety profile are supported by head-to-head clinical data and inclusion in updated treatment guidelines. Physician feedback and refill rates validate real-world differentiation, underpinning Journey’s strategy to dominate the branded oral rosacea segment.
2. Payer Access and Gross-to-Net Optimization
Market access is the critical lever for revenue conversion. With two of the top three group purchasing organizations (GPOs, bulk drug buyers) contracted and the third imminent, Journey will soon have access to over 150 million commercial lives. Quality of coverage—tier placement, step edits, and prior authorization—remains a focus, as management expects improved reimbursement, reduced co-pay assistance, and higher net revenue per script as formulary adoption matures through 2026.
3. Margin Expansion and Cost Discipline
Gross margin gains are driven by product mix shift and operational efficiency. As MROSI and QBREXA, higher-margin brands, comprise a greater share of sales and period costs are controlled, Journey expects continued expansion of operating margins. SG&A growth remains tightly linked to commercial investment, with incremental sales force expansion planned in early 2026 to support further MROSI penetration.
4. Legacy Portfolio Stabilization and Pipeline Augmentation
Base business, primarily legacy products, stabilized in late 2025 after Accutane revenue declines. Management expects the base to remain flat, with incremental growth from one to two new niche dermatology products launching in the second half of 2026, leveraging the established sales infrastructure without diluting focus from MROSI.
5. Publication and Guideline Momentum
Third-party validation through peer-reviewed publications and updated treatment guidelines bolsters payer negotiations and prescriber adoption. Management anticipates up to three new MROSI publications in 2026 and expects inclusion in consensus rosacea treatment guidelines, further supporting commercial uptake.
Key Considerations
Journey Medical’s 2025 performance pivots the company from legacy product dependence to a branded growth trajectory, but execution on payer access and margin leverage will determine the pace and durability of this transition.
Key Considerations:
- Prescription-Revenue Timing Gap: Revenue lags prescription growth due to payer coverage cycles; investors should monitor when this gap closes as formulary wins accrue.
- Refill Dynamics and Chronicity: Rising refill-to-new script ratios (1.4 in Q4) signal growing patient stickiness and long-term revenue per patient, important in chronic conditions like rosacea.
- Gross-to-Net Leverage: Upward pressure on net revenue per script is expected as coverage expands and co-pay assistance wanes, but the pace is dictated by payer adoption timelines.
- SG&A and Sales Force Investment: Incremental sales force expansion is targeted and budgeted, with focus on maximizing MROSI adoption without overextending fixed costs.
- Pipeline Expansion: New product launches are characterized as incremental, with minimal distraction from core brand building, but details on market size and competitive positioning remain limited.
Risks
Key risks include delays in payer coverage and formulary adoption for MROSI, which could prolong the prescription-revenue disconnect and pressure near-term margins. Legacy product erosion remains an overhang, though recent stabilization provides some visibility. Execution risk exists around successful new product launches and the ability to convert early prescriber enthusiasm into durable, broad-based adoption. Macroeconomic and regulatory shifts in drug pricing or reimbursement could also impact gross-to-net realization.
Forward Outlook
For Q1 2026, Journey Medical expects:
- Prescription volumes to surpass Q4 2025, with March tracking strongly after seasonal and weather disruptions in January and February.
- Continued sequential growth in MROSI scripts and refills, supported by incremental sales force expansion.
For full-year 2026, management refrained from issuing explicit revenue guidance but reiterated:
- Expectation to remain adjusted EBITDA positive.
- Improvement in gross-to-net as payer coverage and reimbursement expand.
- Launch of one to two incremental dermatology products in the back half of the year.
Management highlighted that financial guidance will be provided later in the year once payer adoption trends for MROSI are clearer.
- Third GPO contract is expected imminently, unlocking further commercial access.
- Three new MROSI publications and guideline updates may serve as catalysts for payer and prescriber adoption.
Takeaways
Journey Medical’s shift toward branded dermatology is gaining traction, with MROSI driving both top-line growth and margin expansion. The interplay between payer access, script volume, and net revenue per script will determine the pace of revenue inflection and profitability gains in 2026.
- MROSI Is the Growth Engine: Script momentum, refill rates, and prescriber expansion are the key metrics to watch as coverage matures.
- Margin and Cash Strength Provide Flexibility: Gross margin gains and a strong cash position enable further commercial investment and pipeline augmentation without near-term capital risk.
- Watch for Payer Coverage Milestones: Closing the prescription-revenue gap and realizing gross-to-net leverage are the next major inflection points; investors should track formulary wins and net revenue per script trends closely in 2026.
Conclusion
Journey Medical’s 2025 results mark a strategic pivot to branded dermatology, with MROSI’s rapid uptake and margin expansion setting the stage for sustained growth. Execution on payer access and successful incremental launches will be decisive factors in 2026.
Industry Read-Through
DERM’s experience underscores the importance of payer access and real-world evidence in branded specialty pharma launches. The lag between script growth and revenue realization is a structural challenge for new therapeutics, particularly in dermatology, where formulary cycles and co-pay dynamics can materially impact net revenue per script. Competitors launching new branded therapies should anticipate a multi-quarter ramp in reimbursement and margin leverage, even with strong clinical differentiation. Peer companies should note the value of early prescriber targeting, publication strategy, and patient refill tracking as leading indicators of durable brand adoption.